Sitagliptin and Sitagliptin+Metformin are both classified as DPP-4 inhibitors, promising effective management of the condition. With the entry into the Diabetes therapeutic space, Viatris approached us to create e-detailers and LBLs to raise awareness about Sitagliptin/Mylan & Sitagliptin+Metformin/ Mylan among healthcare professionals.